SAB Biotherapeutics, Inc. (NASDAQ:SABSW – Get Free Report) was the recipient of a significant increase in short interest in August. As of August 14th, there was short interest totaling 31,402 shares, an increase of 407.1% from the July 30th total of 6,193 shares. Based on an average daily volume of 52,642 shares, the short-interest ratio is presently 0.6 days.
SAB Biotherapeutics Price Performance
SABSW stock opened at $0.03 on Wednesday. The company’s 50-day moving average is $0.02 and its 200-day moving average is $0.02. SAB Biotherapeutics has a 1 year low of $0.00 and a 1 year high of $0.20.
About SAB Biotherapeutics
SAB Biotherapeutics, Inc is a clinical-stage biopharmaceutical company specializing in the development of fully human polyclonal antibody therapeutics. The company’s core technology, known as the Transchromosomic (Tc) Bovine platform, leverages genetically engineered cattle to produce large volumes of human antibodies in response to targeted antigens. These antibodies are designed to treat a range of infectious diseases and immunological disorders, offering a complementary approach to monoclonal antibodies and traditional vaccines.
The company’s lead programs focus on combating high-priority pathogens, including emerging coronaviruses and other viral threats.
See Also
- Five stocks we like better than SAB Biotherapeutics
- PDD Beat Earnings—So Why Did the Stock Still Fall?
- Tariffs Are Back in Focus: 3 Stocks With a Home-Field Advantage
- Marzetti Stock Confirms Reversal on Earnings Strength, Dividend Growth
- Pathward’s Credit Scare Tests Its Comeback Story
Receive News & Ratings for SAB Biotherapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for SAB Biotherapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
